IDF World Diabetes Congress 2015: Highlights (2)
Vancouver , Canada, 02-Dec-15
New views on incretins
Deacon, MD C.F.
Basic and clinical science – SGLT2 therapies
Forst, Prof. T.
Basic and clinical science – Incretin therapies: DPP-4 inhibitors
Schnell, Prof. O.
Trends in diabetes complication rates: An international comparison
Lalic, Prof. N.
Do we still need more outcome trials in diabetes?
Genovese, MD S.
Supported by Boehringer Ingelheim Pharma GmbH & Co. KG